MediWound announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.
NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns. Commercialization of NexoBrid in these additional regions will commence upon securing authorities approval for market access, which is expected within the next 12 months.
"We are very pleased to strengthen NexoBrid’s European presence by signing new distribution agreements for additional six countries in Europe,” said Sharon Malka, Chief Executive Officer of MediWound. “The addition of these distribution agreements, which cover lucrative European markets, is an extension of our commercial strategy in Europe, driven by our direct sales force accompanied with local distribution agreements, to maximize NexoBrid market potential as we continue to expand the commercialization of NexoBrid towards a substantive cash generating product. We are delighted that NexoBrid will soon be available to treat patients who are suffering from severe burns in these countries."
"We are thrilled at this opportunity to bring NexoBrid to the considerable market of France and to Switzerland . We are confident that Nexobrid will play a major role in the future of burn care in these new markets. We are committed to bringing innovative and life changing therapies to patients in these countries and look forward to expanding our collaboration with MediWound,” Yael Duberstein, Director of GENFA MEDICA SA said.
“For us, as an innovative therapeutic company, NexoBrid brings a new paradigm for burn care patients, both in improving quality of care and cost of care. We are excited about this collaboration and look forward to launching NexoBrid in Greece, Cyprus, Malta and Bulgaria,” George Pavlakis, CEO of Specialty Therapeutics PC said.